Literature DB >> 33359284

Prognostic importance of left atrial size measured by non-contrast cardiac computed tomography - A DANCAVAS study.

Maise Hoeigaard Fredgart1, Jes Sanddal Lindholt2, Axel Brandes3, Flemming Hald Steffensen4, Lars Frost5, Jess Lambrechtsen6, Marek Karon7, Martin Busk4, Grazina Urbonaviciene5, Kenneth Egstrup6, Axel Cosmus Pyndt Diederichsen8.   

Abstract

BACKGROUND: Enlargement of left atrium (LA) is a valuable marker of cardiovascular events, and LA size is readily available while performing non-contrast cardiac computed tomography (NCCT) for preventive purposes. We aimed to evaluate the predictive value of a single LA area from NCCT in a population-based cohort.
METHOD: Mainly men aged 60-75 years from DANCAVAS were included. Traditional risk factors were recorded, and an NCCT scan performed at baseline. Coronary artery calcifications (CAC) score and the largest LA area were measured. LA was indexed to body surface area and categorised into four groups. Data on incident atrial fibrillation (AF), thromboembolic events, heart failure (HF) and death were obtained from Danish national registries.
RESULTS: In total, 14,557 individuals were eligible, excluding those without LA measurement (N = 232) and with heart valve replacement (N = 197). Known AF or HF were respectively excluded from follow-up. Median follow-up time was 2.1 to 3.4 years. In total, 304 developed AF, 149 had thromboembolism, 129 developed HF and 482 died. In adjusted analysis, LA enlargement was associated with AF (HR (95% CI): large 1.99 (1.46-2.71) and very large LA 3.77 (2.31-6.14)) and HF (large 2.40 (1.50-3.85) and very large LA 6.54 (4.07-10.51)). A very large LA significantly increased mortality (HR: 2.01 (1.44-2.82)), and was associated with a two-fold increased risk of thromboembolism; however, not significantly in adjusted analysis (p = 0.09).
CONCLUSION: We demonstrated that determination of LA area from NCCT was an important predictor of AF, HF and death. This knowledge could inform current risk assessment beyond CAC score.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  All cause death; Atrial fibrillation; Heart failure; Left atrial size; Non-contrast cardiac computed tomography; Thromboembolism

Year:  2020        PMID: 33359284     DOI: 10.1016/j.ijcard.2020.12.029

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Mitral Annulus Calcification and Cardiac Conduction Disturbances: A DANCAVAS Sub-study.

Authors:  Jeppe Holm Rasmussen; Maise Hoeigaard Fredgart; Jes Sanddal Lindholt; Jens Brock Johansen; Niels Sandgaard; Abdulrahman Haj Yousef; Selma Hasific; Pernille Sønderskov; Flemming Hald Steffensen; Lars Frost; Jess Lambrechtsen; Marek Karon; Martin Busk; Grazina Urbonaviciene; Kenneth Egstrup; Axel Cosmus Pyndt Diederichsen
Journal:  J Cardiovasc Imaging       Date:  2022-01

2.  Association of Left Atrial Size Measured by Non-Contrast Computed Tomography with Cardiovascular Risk Factors-The Danish Cardiovascular Screening Trial (DANCAVAS).

Authors:  Maise Høigaard Fredgart; Jes Sanddal Lindholt; Axel Brandes; Flemming Hald Steffensen; Lars Frost; Jess Lambrechtsen; Marek Karon; Martin Busk; Grazina Urbonaviciene; Kenneth Egstrup; Lida Khurrami; Oke Gerke; Axel Cosmus Pyndt Diederichsen
Journal:  Diagnostics (Basel)       Date:  2022-01-19

3.  Machine Learning for Electrocardiographic Features to Identify Left Atrial Enlargement in Young Adults: CHIEF Heart Study.

Authors:  Chu-Yu Hsu; Pang-Yen Liu; Shu-Hsin Liu; Younghoon Kwon; Carl J Lavie; Gen-Min Lin
Journal:  Front Cardiovasc Med       Date:  2022-03-01

4.  Cardiovascular outcomes in patients with left atrial enlargement undergoing transcatheter aortic valve implantation.

Authors:  Masahiko Asami; Stephan Dobner; Stefan Stortecky; Dik Heg; Fabien Praz; Jonas Lanz; Taishi Okuno; Daijiro Tomii; David Reineke; Stephan Windecker; Thomas Pilgrim
Journal:  Catheter Cardiovasc Interv       Date:  2022-02-16       Impact factor: 2.585

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.